|
|
Blood, 15 October 2008, Vol. 112, No. 8, pp. 3099-3106.
Prepublished online as a Blood First Edition Paper on June 5, 2008; DOI 10.1182/blood-2008-01-133918.
Previous Article | Next Article 
Submitted January 16, 2008
Accepted May 14, 2008
Paroxysmal nocturnal hemoglobinuria:
natural history of disease subcategories
R. Peffault de Latour, J. Y. Mary, C. Salanoubat, L. Terriou, G. Etienne, M. Mohty, S. Roth, S. de Guibert, S. Maury, J. Y. Cahn, and G. Socie*
Service d'Hematologie Greffe de Moelle, Hopital Saint Louis, Paris, France
Unite INSERM 717 – Universite Paris 7, DBIM, Hopital Saint Louis, Paris, France
Hematologie clinique, Hotel Dieu, Paris, France
Service des Maladies du Sang, Hopital Claude Huriez, Lille, France
Service de Medecine Interne, Groupe Hospitalier Sud, Pessac, France
Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France
Service de Medecine Interne, Hopital Archet, Nice, France
Service d'Hematologie Clinique, Centre hospitalier Pontchaillou, Rennes, France
Service d'Hematologie Clinique, Hopital Henri-Mondor, Paris, France
Service d'Onco-Hematologie, Hopital Michallon, Grenoble, France
* Corresponding author; email: gerard.socie{at}sls.aphp.fr.
The natural history of PNH clinical subcategories (Classic PNH and aplastic anemia (AA) /PNH syndrome) is still unknown. We retrospectively studied 460 PNH patients diagnosed in 58 French hematological centers from 1950 to 2005. The median (SE) follow-up time was 6.8 (0.5) years. The median survival time was 22 (2.5) years. We identified 113 patients with Classic PNH, 224 patients with AA-PNH syndrome, and 93 (22%) intermediate patients who did not fit within these 2 categories. At presentation, Classic PNH patients were older, with more frequent abdominal pain and displayed higher levels of GPI-AP-deficient granulocytes. A time-dependent improved survival was observed. In classic PNH, diagnoses before 1986 (Hazard Ratio (HR) 3.6; p=0.01) and increasing age (p<0.001) were associated with worse survival prognoses, while use of androgens within the first year after diagnosis was protective (HR 0.17; p=0.01). Transfusions before 1996 (HR 2.7; p=0.007) led to lower survival rates in patients with AA-PNH syndrome, while immunosuppressive treatment was associated with better outcomes (HR 0.33; p=0.03). Evolution to thrombosis affected survival in both subcategories (Classic PNH: HR 7.8, p<0.001; AA-PNH syndrome HR 33.0, p<0.001). Evolution to bi- or pancytopenia for Classic PNH (HR 7.3, p<0.001) and malignancies for AA-PNH syndrome (HR 48.8; p<0.001) were associated with worse outcomes. Although clinical presentation and prognosis factors are different, Classic PNH and AA-PNH syndrome present roughly similar outcomes, mainly affected by complications.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. A. Brodsky
How I treat paroxysmal nocturnal hemoglobinuria
Blood,
June 25, 2009;
113(26):
6522 - 6527.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Dingli, L. Luzzatto, and J. M. Pacheco
Neutral evolution in paroxysmal nocturnal hemoglobinuria
PNAS,
November 25, 2008;
105(47):
18496 - 18500.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|